Pfizer, Astellas report detailed data for Xtandi in non-metastatic CRPC

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) reported detailed data from the Phase III PROSPER trial to treat non-metastatic castration-resistant prostate cancer showing that Xtandi enzalutamide plus androgen deprivation therapy led

Read the full 320 word article

User Sign In